Suppr超能文献

舒马曲坦通过激活5-HT1样受体诱导麻醉犬的隐静脉收缩。

Sumatriptan-induced saphenous venoconstriction in the anaesthetized dog through 5-HT1-like receptor activation.

作者信息

Drieu la Rochelle C, O'Connor S E

机构信息

Synthĕlabo Recherche, Cardiovascular Department, Bagneux, France.

出版信息

Br J Pharmacol. 1995 Oct;116(4):2207-12. doi: 10.1111/j.1476-5381.1995.tb15055.x.

Abstract
  1. The role of vasoconstrictor 5-HT1-like receptors in the control of vascular reactivity in vivo has been relatively little studied, particularly with regards to venous function. Using an anaesthetized dog model, we have investigated the haemodynamic profile of the selective 5-HT1-like agonist, sumatriptan, focussing on the reactivity of the saphenous venous bed. The key feature of our experimental model was the implantation of ultrasonic crystals on the adventitial surface of the lateral saphenous vein to provide direct and continuous measurement of drug-induced changes in vein diameter. Saphenous vein pressure was measured simultaneously via a proximal branch. 2. Sumatriptan 1-30 micrograms kg-1, i.v., produced pronounced dose-related reductions in saphenous vein diameter which reached congruent to 40% at the highest dose tested. Sumatriptan also produced modest increases in mean blood pressure, total peripheral resistance and left ventricular end diastolic pressure but had little or no effect on cardiac output, heart rate, cardiac contractility or saphenous venous pressure. Sumatriptan-induced reductions in saphenous vein diameter were strongly antagonized by the 5-HT1-receptor antagonist, methiothepin (0.3 mg kg-1, i.v.) but were unaffected by the 5-HT2 antagonist, ketanserin (0.3 mg kg-1, i.v.). 3. Hence, 5-HT1-like receptor stimulation in vivo can result in a powerful local venoconstrictor effect.
摘要
  1. 血管收缩剂5-羟色胺1样受体在体内控制血管反应性方面的作用研究相对较少,特别是关于静脉功能。我们使用麻醉犬模型,研究了选择性5-羟色胺1样激动剂舒马曲坦的血流动力学特征,重点关注隐静脉床的反应性。我们实验模型的关键特征是在隐静脉外侧的外膜表面植入超声晶体,以直接连续测量药物引起的静脉直径变化。通过近端分支同时测量隐静脉压力。2. 静脉注射1 - 30微克/千克的舒马曲坦可使隐静脉直径显著降低,在测试的最高剂量下达到约40%。舒马曲坦还使平均血压、总外周阻力和左心室舒张末期压力适度升高,但对心输出量、心率、心脏收缩力或隐静脉压力几乎没有影响。5-羟色胺1受体拮抗剂美噻吨(静脉注射0.3毫克/千克)强烈拮抗舒马曲坦引起的隐静脉直径降低,但5-羟色胺2拮抗剂酮色林(静脉注射0.3毫克/千克)对其无影响。3. 因此,体内刺激5-羟色胺1样受体可导致强大的局部静脉收缩效应。

相似文献

本文引用的文献

1
Clinical and experimental effects of sumatriptan in humans.舒马曲坦对人体的临床及实验效果。
Trends Pharmacol Sci. 1993 Apr;14(4):129-33. doi: 10.1016/0165-6147(93)90084-w.
8
Mechanism of the hypotensive effect of ketanserin.酮色林降压作用的机制。
J Cardiovasc Pharmacol. 1982 Sep-Oct;4(5):829-38. doi: 10.1097/00005344-198209000-00020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验